Zogenix, Inc. and Mallinckrodt Inc., a Covidien plc (COV) Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)

6/7/2012 9:21:59 AM

SAN DIEGO, June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Mallinckrodt LLC, the pharmaceuticals business of Covidien (NYSE:COV), today announced an exclusive co-promotion agreement for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System in the United States.

Read at GlobeNewswire

Read Article at

Related Companies

News Categories

• GlobeNewswire

• Mallinckrodt Inc.

• Zogenix, Inc.

• Covidien plc

• Biotech/Pharma - Alliances